Pinnacle Life Science Pvt Ltd receives EIR from USFDA for Baddi facility

United States Food and Drug Administration (US FDA) had successfully conducted an inspection at manufacturing facility of Aarti Drugs Ltd's subsidiary, Pinnacle Life Science Private Limited (Pinnacle) located at Baddi, Himachal Pradesh. Pinnacle is in receipt of the Establishment Inspection Report (EIR). EIR is a report which includes details of audit done.

There are no financial or material impacts as on date. Pinnacle is in receipt of the Establishment Inspection Report (EIR) from USFDA concluding the inspection as Closed. Due to this Pinnacle can export the Formulations in US market once the products get approved by USFDA.

Shares of Aarti Drugs Limited was last trading in BSE at Rs. 506.45 as compared to the previous close of Rs. 511.05. The total number of shares traded during the day was 16407 in over 1061 trades.

The stock hit an intraday high of Rs. 512.60 and intraday low of 503.10. The net turnover during the day was Rs. 8309909.00.

Source : Equity Bulls

Keywords

AartiDrugs INE767A01016 PinnacleLifeScience Baddi USFDA Inspection EIR